Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th
Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th
Recruiting · NCT07655115 · Registry updated 2026-06-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th | autism spectrum disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-06-17 | NCT07655115 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Assistance Publique Hopitaux De Paris | Paris | France | 1 |
| Complejo Asistencial De Zamora Hospital Provincial De Zamora | Zamora | Spain | 1 |
| Hospital Clinic de Barcelona | Barcelona | Spain | 137 |
| Hospital General Universitario Gregorio Marañón | Madrid | Spain | 40 |
| Hospital Universitario de Salamanca | Salamanca | Spain | 29 |